ReviewChinese neurosurgical journal2019
Management of brain metastases: history and the present.
Review in Chinese neurosurgical journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors associated with the local control of brain metastases: a systematic search and machine learning application.BMC medical informatics and decision making · 2024Pooled it
- Trial
- Memory circuit dosimetry in patients with brain metastases treated with Sparing Memory with Advanced Radiosurgery Targeting (SMART) technique.Clinical and translational radiation oncology · 2026Article
- Evaluation of the updated 2022 lung-GPA in NSCLC adenocarcinoma patients with brain metastases: analysis of prognostic factors in a German clinical cohort.Radiation oncology (London, England) · 2026Article
- Article
- A Comprehensive Analysis of the Management of Brain Metastases-Experience from a South-Eastern European Neurosurgical Centre.Medicina (Kaunas, Lithuania) · 2025Article
- Neoadjuvant stereotactic radiotherapy for brain metastasis: a review of ongoing clinical trials.Discover oncology · 2025Review
- Diagnostic, Therapeutic, and Prognostic Applications of Artificial Intelligence (AI) in the Clinical Management of Brain Metastases (BMs).Brain sciences · 2025Review
- Stereotactic radiosurgery versus whole-brain radiotherapy for intracranial metastases: A systematic review and meta-analysis.Surgical neurology international · 2025Review
- Article
- De novo GTP synthesis is a metabolic vulnerability for the interception of brain metastases.Cell reports. Medicine · 2024Article
- Survival after Stereotactic Radiosurgery in the Era of Targeted Therapy: Number of Metastases No Longer Matters.Current oncology (Toronto, Ont.) · 2024Article
- Evaluating the Efficacy of Machine Performance Checks as an Alternative to Winston-Lutz Quality Assurance Testing in the TrueBeam Linear Accelerator with HyperArc.Diagnostics (Basel, Switzerland) · 2024Article
- KRASOncoTargets and therapy · 2024Review
- Artificial Intelligence in Neuroradiology: A Review of Current Topics and Competition Challenges.Diagnostics (Basel, Switzerland) · 2023Review
- Is adagrasib just another sotorasib?-or, should we differentiate their usage according to patients' clinical presentation?Translational lung cancer research · 2023Article
- Comparison of 116 Radiosurgery Treatment Plans for Multi-Leaf and Cone Collimator on a Varian Edge Linac: Are Cones Superior in the Daily Routine?Life (Basel, Switzerland) · 2023Article
- Stereotactic radiosurgery versus whole-brain radiotherapy after resection of solitary brain metastasis: A systematic review and meta-analysis.World neurosurgery: X · 2023Article
- Validation and discussion of clinical practicability of the 2022 graded prognostic assessment for NSCLC adenocarcinoma patients with brain metastases in a routine clinical cohort.Frontiers in oncology · 2023Article
- Therapeutic Options for Brain Metastases in Gynecologic Cancers.Current treatment options in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases are significant causes of morbidity or mortality for patients with metastatic cancer. With the application of novel systematic therapy and improvement of overall survival, the prevalence of brain metastases is increasing. The paradigm of treatment for brain metastases evolved rapidly during the last 30 years due to the development of technology and emergence of novel therapy. Brain metastases used to be regarded as the terminal stage of cancer and left life expectancy to only 1 month. The application of whole brain radiotherapy for patients with brain metastases increased the life expectancy to 4-6 months in the 1980s. Following studies established surgical resection followed by the application of whole brain radiotherapy the standard treatment for patients with single metastasis and good systematic performance. With the development of stereotactic radiosurgery, stereotactic radiosurgery plus whole brain radiotherapy provides an alternative modality with superior neurocognitive protection at the cost of overall survival. In addition, stereotactic radiosurgery combined with whole brain radiotherapy may offer a promising modality for patients with numerous multiple brain metastases who are not eligible for surgical resection. With the advancing understanding of molecular pathway and biological behavior of oncogenesis and tumor metastasis, novel targeted therapy including tyrosine-kinase inhibitors and immunotherapy are applied to brain metastases. Clinical trials had revealed the efficacy of targeted therapy. Furthermore, the combination of targeted therapy and radiotherapy or chemotherapy is the highlight of current investigation. Advancement in this area may further change the treatment paradigm and offer better modality for patients who are not suitable for surgical resection or radiosurgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.